David Spigel, MD

Articles

Unmet Needs and Future Perspectives in the NSCLC Treatment Landscape

February 21st 2023

Looking to the future, a panel of experts offer closing remarks on promising developments and unmet needs in the treatment of NSCLC.

Neoadjuvant Therapy and Other Emerging Therapies in Early Stage NSCLC

February 14th 2023

Experts discuss the role of neoadjuvant therapy and other emerging therapies in the treatment of early-stage NSCLC.

Treatment Approach for Patients With Stage II-IIIA NSCLC

February 14th 2023

Jaspal Singh, MD, MHS, shares insights on treatment strategies for patients with stage II-IIIA NSCLC.

Patient Profile 2: Former Smoker Diagnosed With NSCLC

February 7th 2023

David H. Harpole Jr, MD, presents a case of a former smoker diagnosed with NSCLC, and David Spigel, MD, offers his initial impressions.

Choosing Appropriate Patients for Surgical Resection in NSCLC

February 7th 2023

An expert panel shares perspectives on how to choose the appropriate patients with non-small cell lung cancer for lung resection.

Therapies Targeting Specific Molecular Alterations in NSCLC

January 31st 2023

A panel of distinguished experts discuss how detection of actionable mutations affect their treatment choices in non-small cell lung cancer.

Adjuvant Therapy in Early Stage NSCLC

January 31st 2023

David Spigel, MD, and David H. Harpole Jr, MD, describe when adjuvant therapy is recommended in early stage NSCLC and discuss data from recent clinical trials of adjuvant therapy.

Treatment Approach for Patients With Stage IB Disease

January 24th 2023

A panel of experts in the treatment of NSCLC discusses how they manage patients with stage IB disease.

Workup and Molecular Testing for a Patient with NSCLC

January 24th 2023

David H. Harpole Jr, MD, a thoracic surgeon, details his workup approach and discussed molecular testing for patients who present with NSCLC.

Patient Profile 1: A 57-Year-Old Woman Diagnosed With NSCLC

January 17th 2023

David Spigel, MD, presents a patient case of a 57-year-old woman with NSCLC, and Jaspal Singh, MD, MHS, discusses his approach to initial evaluation.

Multidisciplinary Care in Non-Small Cell Lung Cancer

January 17th 2023

A panel of experts introduce themselves and explain their approaches to multidisciplinary care in treating non-small cell lung cancer.

Dr. Spigel Discusses Advances in Early-Stage Lung Cancer

February 1st 2021

David Spigel, MD, discusses advances in early-stage lung cancer treatment.

Dr. Spigel Reflects on the PACIFIC Study in NSCLC

October 5th 2018

David Spigel, MD, chief scientific officer, director, Lung Cancer Research Program, principal investigator, Sarah Cannon Research Institute, reflects on the results of the PACIFIC trial in patients with non–small cell lung cancer.

Dr. Spigel on the Rationale Behind the PACIFIC Trial

March 8th 2018

David Spigel, MD, chief scientific officer, director, Lung Cancer Research Program, principal investigator, Sarah Cannon Research Institute, discusses the rationale behind the design of PACIFIC, a trial that investigated the use of durvalumab (Imfinzi) in patients with locally advanced, unresectable stage III lung cancer.

Dr. Spigel on FDA Approval of Pembrolizumab/Chemo Combo in NSCLC

May 11th 2017

David Spigel, MD, chief scientific officer, director, Lung Cancer Research Program, principal investigator, Sarah Cannon Research Institute, discusses the FDA approval of pembrolizumab plus chemotherapy as a frontline treatment for patients with non–small cell lung cancer (NSCLC).

Dr. Spigel on Pembrolizumab/Chemo Combo in First-Line NSCLC

March 27th 2017

David Spigel, MD, chief scientific officer, director, Lung Cancer Research Program, principal investigator, Sarah Cannon Research Institute, discusses the results of cohort G from the KEYNOTE-021 trial, which explored pembrolizumab (Keytruda) combined with pemetrexed/carboplatin as a frontline treatment for patients with nonsquamous non–small cell lung cancer (NSCLC).

Dr. Spigel on CheckMate-331 Trial for SCLC

June 29th 2016

David Spigel, MD, chief scientific officer, director, Lung Cancer Research Program, principal investigator, Sarah Cannon Research Institute, discusses the ongoing CheckMate-331 trial, which is investigating nivolumab (Opdivo) versus chemotherapy in relapsed patients with small cell lung cancer (SCLC) after first-line platinum-based chemotherapy.

Dr. Spigel Discusses the Development of Onartuzumab for the Treatment of Lung Cancer

December 2nd 2014

David Spigel, MD, director, Lung Cancer Research Program, Sarah Cannon Research Institute, discusses the development of onartuzumab for the treatment of patients with lung cancer.

Dr. Spigel Discusses Results from a Phase III Study Exploring Eribulin in NSCLC

November 1st 2014

David Spigel, MD, director of Lung Cancer Research at the Sarah Cannon Research Institute, discusses results from a phase III study exploring eribulin for the treatment of patients with non-small cell lung cancer.

Dr. Spigel Discusses MPDL3280A Development in Lung Cancer

June 3rd 2014

David Spigel, MD, director of Lung Cancer Research at the Sarah Cannon Research Institute, discusses current trials involving MPDL3280A in lung cancer.